(IN BRIEF) AstraZeneca has entered into an exclusive global licence agreement with Dizal Pharmaceutical for Zegfrovy, also known as sunvozertinib, an oral irreversible EGFR inhibitor for lung cancer. The deal gives AstraZeneca worldwide rights to develop and commercialise the medicine. … Read the full press release
Posted in Business, Financial, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, ASCO 2026, AstraZeneca, AstraZeneca Adds Zegfrovy to Oncology Pipeline Through Global Licence Deal With Dizal, AstraZeneca Targets EGFR Exon 20 Lung Cancer With Worldwide Rights to Zegfrovy, breakthrough therapy designation, cancer treatment, CDE, Center for Drug Evaluation, Dave Fredrickson, Dizal Grants AstraZeneca Global Development and Commercialisation Rights for Zegfrovy, Dizal Pharmaceutical, Dr Xiaolin Zhang, EGFR exon 20 insertion mutations, EGFR inhibitor, EGFR-mutated NSCLC, first-line NSCLC, global licence agreement, irreversible EGFR inhibitor, lung cancer, NCCN Guidelines, New England Journal of Medicine, non-small cell lung cancer, NSCLC, oncology, oncology haematology, oral EGFR inhibitor, pharmaceutical licensing, Phase III Trial, platinum-based chemotherapy, sunvozertinib, Supplemental New Drug Application, targeted therapy, US FDA, WU-KONG28, Zegfrovy
(IN BRIEF) AB Volvo has announced the winners of the 2026 Assar Gabrielsson Foundation Prize, recognising achievements in both basic and clinical cancer research. Ketan Thombare received the award in the basic science category for his research into RNA modifications … Read the full press release
Posted in Automotive, Awards, Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, Science, Sweden, Technology
Tagged AB Volvo, AB Volvo Announces 2026 Assar Gabrielsson Foundation Prize Winners Recognising Advances in Cancer Research, Assar Gabrielsson Foundation, basic science research, biomarkers, cancer research, clinical research, Ella Äng Eklund, Eva Forssell Aronsson, glioma, Ketan Thombare, KRAS mutation, Leading Cancer Researchers Honoured with 2026 Assar Gabrielsson Foundation Awards by AB Volvo, Louise Carstam, lung cancer, Neuroblastoma, Sahlgrenska Academy, University of Gothenburg
(IN BRIEF) Researchers from The Institute of Cancer Research and Queen’s University Belfast have developed an AI tool to improve the accuracy and consistency of PD-L1 scoring in lung cancer diagnosis. The system uses deep learning to assist pathologists in … Read the full press release
Posted in Artificial Intelligence (AI), Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged artificial intelligence, biomarker analysis, digital pathology, immunotherapy, lung cancer, Manuel Salto-Tellez, non-small cell lung carcinoma, NSCLC, oncology, PD-L1, precision medicine, Queen's University Belfast, Researchers advance digital pathology with new AI solution for more reliable lung cancer diagnostics, Scientific Reports, The Institute of Cancer Research, TPS, Tumour Proportion Score
(IN BRIEF) GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early clinical data showing durable responses in patients with extensive-stage disease. SCLC, … Read the full press release
Posted in Business, Healthcare, Marketing, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, clinical trials, colorectal cancer, EMA, ES SCLC, extensive stage SCLC, FDA, GSK, GSK advances investigational cancer therapy risvutatug rezetecan with sixth global designation supporting development in solid tumours, Hansoh Pharma, Japan Ministry of Health Labour and Welfare, lung cancer, oncology, orphan drug designation, Phase III Trial, PRIME designation, prostate cancer, Ris Rez, risvutatug rezetecan, SCLC, Small cell lung cancer
(IN BRIEF) UK researchers have developed a pioneering blood test using Fourier Transform Infrared microspectroscopy that can detect a single lung cancer cell circulating in the bloodstream. The technique analyses the unique chemical fingerprint of cancer cells, offering a simpler, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Sports, United Kingdom
Tagged blood test, Breakthrough FT IR Technique Could Transform Early Lung Cancer Detection, Cancer Detection, cancer monitoring, circulating tumour cells, early diagnosis, FT IR microspectroscopy, infrared spectroscopy, Josep Sulé Suso, Keele University, liquid biopsy, Loughborough University, lung cancer, NHS cancer care, oncology research, Paul Roach, University Hospitals of North Midlands NHS Trust
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged anti-CD30, Brentuximab Vedotin, Cancer Immunotherapy, cancer research, combination treatment, ICB resistance, immune checkpoint blockade, immunotherapy breakthroughs, lung cancer, melanoma, metastatic cancer, Newcastle University, pancreatic cancer, PD-1, skin cancer, solid tumors, T regulatory cells
(IN BRIEF) The University of Exeter has developed a new algorithm for interpreting blood test results, helping GPs detect potential cancer warning signs earlier, particularly through variations in platelet count. The Royal Devon University Healthcare NHS Foundation Trust is the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged algorithm, Australia, blood test, bowel cancer, CANADA, Cancer Detection, Cancers journal, David Walton, Devon, early diagnosis, early warning signs, England, Exeter HealthTech Research Centre, general practitioners, GP, High or Elevated Level of Platelets (HELP) Flag, lung cancer, medical research, National Institute for Health and Care Research, NHS, patient outcomes, personalized thresholds, platelet count, platelet variation, Professor Sarah Bailey, RDUH, Royal Devon University Healthcare NHS Foundation Trust, University of Exeter
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release
Posted in Business, Environment, European Union, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Daiichi Sankyo, Dave Fredrickson, Enhertu, EU approval, HER2-Mutant, Ken Keller, lung cancer, Martin Reck, monotherapy, NSCLC, partnership, sustainability
(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, chemotherapy, EGFR, FLAURA2, lung cancer, osimertinib, Susan Galbraith, Tagrisso, Treatment USA
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) Researchers at the University of Liverpool, in collaboration with Janssen Pharmaceutica, have made significant progress in using blood proteins to predict future lung cancer. The study analyzed blood samples taken from healthy participants up to ten years before … Read the full press release
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, AZD5335, AZD9592, early-stage, Imfinzi, lung cancer, oncology, Susan Galbraith, treatment
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer Immunotherapy, chemotherapy, FDA, Levi Garraway, lung cancer, non-small cell lung cancer, NSCLC, Real-Time Oncology Review, Roche, sBLA, supplemental Biologics License Application, Tecentriq®, treatment, tumours
(PRESS RELEASE) FREIBURG, Germany, 1-Jul-2021 — /EuropaWire/ — Prostate cancer is the second most common cancer. According to the American Cancer Association, 1 in every 8 men will be diagnosed with it in their lifetime. In 2018 around 1.2 million … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science
Tagged American Cancer Association, B66, bioscience, Biotech, bladder, breast, Cancer, colorectal, Dr Eric Metzger, Freiburg, Germany, histone methyltransferase, inhibitors, KMT9, lung cancer, Manfred Jung, Mike Dunckley, pharma, Professor Manfred Jung, Professor Roland Schule, Professors Roland Schule, prostate cancer, prostate tumours, University of Freiburg
(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged bladder cancer, Dave Fredrickson, Imfinzi, Io, lung cancer, NSCLC, oncology, SCLC, Small cell lung cancer, Victoria M. Villaflor MD
uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining positivity Roche advances personalised healthcare with development of image analysis algorithms using artificial intelligence Faster, more accurate … Read the full press release
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Alecensa®, alectinib, anaplastic lymphoma kinase, ASCO virtual newsroom, ASCO20 Virtual Scientific Program, atezolizumab, cancer care, Cancer Immunotherapy, clinical data tiragolumab, Levi Garraway M.D. Ph.D., lung cancer, Roche, Tecentriq®
This year’s Swiss Aerosol Award goes to Maria Muñoz. The Empa researcher investigated the emission behavior of so-called GDI engines (gasoline-direct injection). Her results are alarming: GDI vehicles emit up to 17 times more carcinogenic substances than modern diesel vehicles. … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?